Verena G.
- Country
- Germany
- Department
- 2605; Early Clinical Trials Unit
Research Overview
- Phase 3 Double-Blind Study of Ivosidenib in Adults with IDH1-Mutant Locally Advanced or Metastatic Conventional Chondrosarcoma
- Phase III Randomized Study of CPX-351 Versus Standard Chemotherapy in Adults with Newly Diagnosed AML and Intermediate or Adverse Genetic Risk
- A Modular Phase I/II, Open-label, Multi-Centre Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants with Advanced Haematologic Malignancies with KMT2Ar, NPM1m, or Other Genotypes Associated with HOX Overexpression
Data & Insights
Has run more than one trial at 7 of 101 partner sites.
Specializations
Oncology - Solid Tumors
This investigator specializes in treating advanced solid tumors and has particular expertise in leiomyosarcoma, focusing on metastatic disease management.
- Advanced Cancer Treatment
- Metastatic Leiomyosarcoma
- Ewing Sarcoma
The investigator's work encompasses innovative combination therapies for various types of solid tumors.
Hematologic Malignancies
Specializes in treating acute myeloid leukemia (AML) with particular focus on cases with specific genetic profiles and myelodysplastic syndrome (MDS).
- IDH1-Mutated AML
- AML with Intermediate/Adverse Genetics
- Therapy-Related AML
The investigator works with novel therapeutic approaches for patients who cannot receive intensive chemotherapy.
Precision Medicine
Focuses on targeted therapies and genetic-based treatment approaches in oncology, particularly in cases with specific molecular markers.
- Genetic-Based Cancer Treatment
- Molecular Targeted Therapies
- Combination Treatment Strategies
The investigator develops personalized treatment approaches based on specific genetic and molecular characteristics.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.